A Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 (Galcanezumab) in Japanese Patients With Episodic Migraine

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 (Galcanezumab) in Japanese Patients With Episodic Migraine

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Galcanezumab (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Aug 2017 Planned End Date changed from 1 Jan 2019 to 1 Feb 2019.
    • 25 Aug 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Feb 2019.
    • 20 Apr 2017 Results from this trial will be presented at the American Academy of Neurology (AAN) annual meeting 2017, as reported in an Eli Lilly and Company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top